Pulmonary Thromboembolism Induced by Intravenous Immunoglobulin Therapy for Stevens-Johnson Syndrome : A Case Report

2019 ◽  
Vol 81 (3) ◽  
pp. 170-174 ◽  
Author(s):  
Taketoshi IDE ◽  
Maiko OHNO ◽  
Takamichi ITO ◽  
Karin TSUKAMOTO ◽  
Anna HIRANO ◽  
...  
2021 ◽  
Vol 9 ◽  
pp. 232470962110374
Author(s):  
Tomoyo Oguri ◽  
Shinji Sasada ◽  
Satoko Shimizu ◽  
Risa Shigematsu ◽  
Yumi Tsuchiya ◽  
...  

A 76-year-old man was admitted to our hospital with Guillain-Barré syndrome (GBS), presenting with facial palsy, dysarthria, and dysphagia as Grade 3 immune-related adverse events (irAEs) due to pembrolizumab administration for Stage IV lung adenocarcinoma. Although prednisolone (1 mg/kg) was started for GBS due to the irAE, dark erythema and skin eruptions appeared on the patient’s torso. Then erosion was observed on 18% of the body surface area and skin biopsy was performed. Finally, the patient was diagnosed with Stevens-Johnson syndrome/toxic epidermal necrosis overlap. Intravenous immunoglobulin therapy was started, and the skin symptoms improved, with the erosion becoming epithelial. He died of aspiration pneumonia related to GBS, although his neurological symptoms had improved after steroid and intravenous immunoglobulin therapy. This is the first reported case of pembrolizumab-induced GBS and Stevens–Johnson syndrome/toxic epidermal necrosis overlap. It is necessary to be careful that the possibility of other severe irAEs may occur simultaneously.


Sign in / Sign up

Export Citation Format

Share Document